Skip to main content

01.12.2018 | Research article | Ausgabe 1/2018 Open Access

BMC Complementary and Alternative Medicine 1/2018

Shuang-Huang-Lian prevents basophilic granulocyte activation to suppress Th2 immunity

BMC Complementary and Alternative Medicine > Ausgabe 1/2018
Qiaoling Fei, Yixin Han, Ruijuan Qi, Yuan Gao, Lei Fang, Rui Hou, Runlan Cai, Yun Qi
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi: https://​doi.​org/​10.​1186/​s12906-017-2071-y) contains supplementary material, which is available to authorized users.



Basophilic granulocytes (BGs) not only initiate the induction of Th2 cell differentiation, but also amplify the ongoing Th2 response. Shuang-Huang-Lian (SHL) is clinically used for relieving type I hypersensitivity by continuous treatment for several weeks.


ELISA, flow cytometry, magnetic activated cell sorting, isoelectric precipitation, hybridoma technique, transfection and luciferase reporter assay were used in this study. The statistical analysis was performed using a one-way ANOVA.


Our recently published study demonstrated that SHL exerted a remarkable effect on mast cell stabilization. Herein, we sought to elucidate the effect of SHL on shrimp tropomyosin (ST)-induced Th2 immunity and its underlying mechanisms. The obtained data showed that continuous treatment with SHL significantly suppressed ST-stimulated Th2-cytokines release and IgE synthesis. A mechanistic study indicated that SHL not only reduced BG early IL-4 release before ST-specific IgE (sIgE) production, but also inhibited BG activation in the presence of sIgE, including suppressing CD200R surface expression and decreasing IL-4 production. Moreover, SHL markedly decreased the cytosolic Ca2+ (Ca2+[c]) level and inhibited the nuclear factor of activated T cells (NFAT) activation in RBL-2H3 cells.


Collectively, SHL potently reduces ST-induced Th2 immunity by inhibiting the BG Ca2+-NFAT pathway and, thus, suppressing the early IL-4 release before sIgE synthesis and inhibiting BG activation in the presence of sIgE. This study provides the pharmacological basis for the clinical use of SHL to relieve type I hypersensitivity by a successive dose regimen.
Additional file 1: Figure S1. Schedule for the preparation of the ST-sensitized mice. (DOCX 115 kb)
Additional file 2: Figure S2. Proportion of basophils in the splenocytes separated by a MACS system using a FACSCalibur flow cytometer. (DOCX 174 kb)
Additional file 6: Figure S3. Effect of SHL on the viability of basophil-rich splenocytes. The cells were treated with SHL at the indicated concentrations for 24 h. Cell viability was assessed using an MTS assay. (DOCX 84 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Complementary and Alternative Medicine 1/2018 Zur Ausgabe